Amphion Partner Company, WellGen, Hires New Chief Scientific Officer
Rawson to Oversee Scientific Integrity of WellGen Programs and Advance Collaborations with Food and Beverage Industry Leaders
New Brunswick, NJ, 18 December 2007 - WellGen, Inc., a biotechnology company using nutrigenomics to discover and develop food ingredients for wellness products, today announced the appointment of Nancy E. Rawson, M.Sc., Ph.D., as Chief Scientific Officer.
Dr. Rawson fills a newly created position that will report directly to the CEO. Dr. Rawson, 51, joins WellGen at a critical stage in its development, as the Company has just brought its first functional food ingredient product to market and is conducting human studies for its second, while seeking to significantly expand the number of ingredients in its pipeline. In addition, the Company is completing the installation of a new, state-of-the-art molecular biology and natural products chemistry laboratory.
Dr. Rawson comes to WellGen with an extensive background in food, nutrition and basic biomedical research. Dr. Rawson most recently worked at the Monell Chemical Senses Center in Philadelphia, PA, as an Associate Member. The Monell Center is an independent scientific institute dedicated to basic research on the senses of taste, smell and chemosensory irritation. During her tenure there, Dr. Rawson built relationships with well-recognized leaders in the food and beverage industry as well as with researchers throughout the world.
Previously, Dr. Rawson was a Senior Nutrition Research Associate at the Campbell Soup Company. She also has held numerous advisory and university teaching positions.
Dr. Kathleen Mullinix, Chief Executive Officer of WellGen, said, “We are fortunate to have Nancy Rawson, who is an outstanding scientist, join our company, and we look to her to ensure that our products’ scientific foundations will meet the very highest standards. Her background in both research and industry will also enable her to be an effective leader in working with partner companies to bring new functional foods and beverages to market.”
Richard Morgan, CEO of Amphion Innovations plc (LSE: AMP), a leading investor in WellGen, said, “Nancy Rawson has an excellent reputation in the food industry and an exceptional track record of scientific accomplishments. These will help WellGen continue to establish its leading position in the growing functional foods and beverages industry.”
During her career, Dr. Rawson has received numerous honors and awards in bioscience and nutrition, and has often been quoted in the media as an authority in these fields. She is a frequent lecturer and conference panelist, and has authored and collaborated on a wide range of publications for both academic and non-technical audiences. She graduated with a Bachelor of Science degree from Fairfield University, Fairfield, CT, earned a Masters of Science in Nutrition from the University of Massachusetts, Amherst, and received a Ph.D. in Biology from the University of Pennsylvania.
For further information please contact
WellGen, Inc.
Patricia Lucas-Schnarre Vice President, Marketing
732-565-3890, ext. 4403
David A. Kronfeld Communications
David A. Kronfeld
917-408-1940
Amphion Innovations plc
Charlie Morgan, Director of Communications
+1 212 210 6224
About Amphion Innovations plc
Amphion Innovations plc (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors. Amphion uses a focused,hands-on company building approach based on decades of experience in both the US and UK.
On the web: www.amphionplc.com
About WellGen
WellGen, Inc., based in North Brunswick, NJ, is a biotechnology company that is discovering and developing products for food, therapeutics, and dietary supplement markets with a strategic focus on functional foods. WellGen's proprietary technology platform is a method of screening the effect of food and related substances on the expression of genes associated with human health conditions. The company has developed proprietary substances that help maintain health and reduce risk and severity for a variety of diseases.
Please visit our website at www.wellgen.com for more information.
